Immuneel Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 100.00 Cr
as on 15-11-2024
- Paid Up Capital ₹ 0.46 M
as on 15-11-2024
- Company Age 5 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 441.27%
(FY 2023)
- Profit -26.81%
(FY 2023)
- Ebitda -38.00%
(FY 2023)
- Net Worth 177.46%
(FY 2023)
- Total Assets 17.77%
(FY 2023)
About Immuneel Therapeutics
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 100.00 Cr and a paid-up capital of Rs 0.46 M, as per Ministry of Corporate Affairs (MCA) records.
Prem Pavoor, Amit Mookim, Saif Hasani, and Three other members serve as directors at the Company.
- CIN/LLPIN
U24230KA2018PTC119691
- Company No.
119691
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Dec 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Immuneel Therapeutics Private Limited offer?
Immuneel Therapeutics Private Limited offers a wide range of products and services, including Te Homef, Quilt Bedding Set, Heatig, Water Preheaters, Ac Refrigeration Equipment, R32 Refrigerant Gas, Writing Instruments, Quran Read Pen, Stone, Garnet Bracelet.
Who are the key members and board of directors at Immuneel Therapeutics?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prem Pavoor  | Director | 20-Apr-2022 | Current |
| Kiran Shaw | Director | 20-Dec-2018 | Current |
| Amit Mookim | Director | 29-Oct-2024 | Current |
| Saif Hasani | Director | 19-Sep-2024 | Current |
Siddhartha Mukherjee  | Director | 20-Apr-2022 | Current |
| Ranjan Pai | Director | 20-Dec-2018 | Current |
Financial Performance and Corporate Structure Insights of Immuneel Therapeutics.
Immuneel Therapeutics Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 441.27% increase. The company also saw a substantial fall in profitability, with a 26.81% decrease in profit. The company's net worth Soared by an impressive increase of 177.46%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Immuneel Therapeutics?
In 2023, Immuneel Therapeutics had a promoter holding of 31.08% and a public holding of 68.92%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Eight Roads Investment Advisors Private LimitedActive 17 years 5 monthsPrem Pavoor is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Immuneel Therapeutics?
Immuneel Therapeutics has a workforce of 96 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Immuneel Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Immuneel Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
